PCRX Pacira BioSciences, Inc.Stock Price & Overview
Stock Price & Overview
$14.53
PCRX Stock Price
Quant Ranking
PCRX Analysis
PCRX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to PCRX
ETFs Holding PCRX
PCRX Company Profile
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Revenue
PCRX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
PCRX Ownership
PCRX Peers
Risk
Technicals
PCRX Transcripts
Investor Presentations
PCRX SEC Filings
Press Releases
PCRX Income Statement
PCRX Balance Sheet
PCRX Cash Flow Statement
PCRX Long Term Solvency
Discover More
You may be interested in: